依达拉奉联合丁苯酞治疗急性缺血性脑卒中疗效观察

Clinical observation of edaravone combined with butylphthalide in the treatment of acute ischemic stroke

目的观察急性缺血性脑卒中患者接受依达拉奉联合丁苯酞治疗的临床效果。方法随机选取前来我院就诊的急性缺血性脑卒中患者90例为研究对象(2015年5月~2017年5月),根据患者入院单双号将其分成研究组和对照组,依达拉奉联合丁苯酞方案和单独应用依达拉奉方案分别用于两组患者临床治疗,对比分析不同组别患者临床各指标。结果治疗后研究组患者hs-CRP(超敏C反应蛋白)和TNF-α(肿瘤坏死因子)炎症因子均明显低于对照组;研究组患者临床疗效97.78%,对照组77.78%,组间比较有统计学意义研究组治疗效果更好(P<0.05);同时治疗后研究组患者NIHSS评分(神经功能评分)明显低于对照组(P<0.05)。但是两组患者临床不良反应发生率组间比较差异无统计学意义(P>0.05)。结论急性缺血性脑卒中患者临床治疗中应用依达拉奉联合丁苯酞治疗,能够有效改善患者神经功能缺损程度及炎症因子,控制病情发展提高临床疗效,临床应用价值明显。

Objective To observe the clinical effect of edaravone combined with butylphthalide in patients with acute ischemic stroke. Methods Ninety patients with acute ischemic stroke who came to our hospital were randomly selected as experimental samples（from May 2015 to May 2017）.The patients were divided into the study group and the control group according to the admission number.Edaravone combined with butylphthalide regimen and edaravone alone were used in the clinical treatment of two groups of patients.The clinical indexes of different groups of patients were compared and analyzed. Results After treatment,the hs-CRP（high sensitivity C reactive protein） and TNF-α（tumor necrosis factor） inflammatory factors in the study group were significantly lower than those in the control group.The clinical efficacy of the study group was 97.78%,and that of the control group was 77.78%.There was a statistically significant difference between the two groups, and the treatment effect of the study group was better（P 0.05）.At the same time,the NIHSS score（neurological function score） of the study group was significantly lower than that of the control group（P 0.05）.However,there was no significant difference in the incidence of adverse reactions between the two groups（P 0.05）. Conclusion Edaravone combined with butylphthalide in the clinical treatment of patients with acute ischemic stroke can effectively improve the degree of neural function defect and inflammatory factors,control the development of the disease and improve the clinical efficacy,clinical application value is obvious.